/Investor DB

Intervest — 2023 Investments

2 investments dated 2023 · listed companies and verified rows first · show all

OncoResponseoncoresponseinc.comMay 2023 · $14M

Clinical-stage immuno-oncology company developing antibodies derived from the immune systems of 'Elite' cancer responders.

BiotechHouston, US

Alice Bexon(Executive Officer)inClifford J. Stocks(Director, Executive Officer)inKamal D. Puri(Executive Officer)inChris Russell(Executive Officer)inRuss Hawkinson(Executive Officer)

BoardSteven Gillis(Director)in

Co-investors3B Future Health FundCanaan PartnersGreatPoint VenturesRiverVest Venture PartnersAlexandriaARCH Venture Partners+5 more

올거나이즈allganize.aiin𝕏Nov 2023

Allganize builds AI Coworkers and an enterprise AI platform called Alli, offering vertically integrated tools spanning LLM selection, RAG 2.0 document handling, agent execution, deployment, and security compliance.

AI & Machine LearningEnterprise SoftwareSaaSPleasanton, US

Changsu Lee(Founder & CEO)in

BoardYoon Kang(Director)Yasuhiko Yurimoto(Director)

Co-investorsAtinum Investment Co. Ltd.KDDI Open Innovation FundLaguna InvestmentLG Technology VenturesSk Telecom Venture Capital, LlcSpark Labs Korea Accelerator Fund 4+5 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.